Detalles de la búsqueda
1.
Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015).
Breast Cancer Res
; 25(1): 39, 2023 04 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37046348
2.
Equality, diversity, and inclusion in oncology clinical trials: an audit of essential documents and data collection against INCLUDE under-served groups in a UK academic trial setting.
BMC Med Ethics
; 24(1): 105, 2023 11 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38017503
3.
Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study.
Breast Cancer Res
; 24(1): 61, 2022 09 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36096872
4.
Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial.
Lancet Oncol
; 21(11): 1443-1454, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33152284
5.
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Lancet Oncol
; 21(10): 1296-1308, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32919527
6.
Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial.
Lancet Oncol
; 20(7): 1023-1034, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31160249
7.
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.
Lancet Oncol
; 14(10): 989-98, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23902874
8.
ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer.
Cancer Discov
; 14(2): 274-289, 2024 Feb 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37982575
9.
Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer.
Clin Cancer Res
; 30(4): 895-903, 2024 02 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38078899
10.
Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727).
Clin Cancer Res
; 29(18): 3691-3705, 2023 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37574209
11.
Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010).
Clin Cancer Res
; 29(23): 4751-4759, 2023 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37773077
12.
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.
Lancet Oncol
; 12(8): 763-72, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21723781
13.
Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer.
Trials
; 23(1): 372, 2022 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35526005
14.
Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2- Breast Cancer.
Clin Cancer Res
; 28(1): 163-174, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34645649
15.
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer.
EBioMedicine
; 83: 104205, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35985932
16.
Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial.
JAMA Oncol
; 7(9): 1291-1301, 2021 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34264305
17.
Genomic profile of advanced breast cancer in circulating tumour DNA.
Nat Commun
; 12(1): 2423, 2021 04 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-33893289
18.
Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study.
Breast Cancer Res Treat
; 124(1): 153-61, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-20730486
19.
Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK - A16037).
Ther Adv Med Oncol
; 12: 1758835920975352, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33854564
20.
ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials.
Clin Cancer Res
; 26(19): 5172-5177, 2020 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32546646